Robin M. van Dongen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robin M. van Dongen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Gerrit L. J. Onderwater
Department of Neurology Leiden University Medical Center Leiden The Netherlands
3 shared publications - Michel Dominique Ferrari
Leiden University Medical Center
3 shared publications Amy C. Harms
Analytical BioSciences and Metabolomics, Leiden Academic Center for Drug Research, Leiden, The Netherlands
2 shared publications- Arn M. J. M. van Den Maagdenberg
Leiden University Medical Center
2 shared publications - Aster V. E. Harder
Leiden University Medical Center
2 shared publications Gisela M. Terwindt
Department of Neurology Leiden University Medical Center Leiden The Netherlands
2 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (7)
Endocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression
Background: Disruption of the endocannabinoid system has been implicated in both migraine and depression, which are frequently comorbid in patients. Nevertheless, supporting evidence for this hypothesis is limited. Hence, we investigated whether the endocannabinoid system is disrupted in interictal migraine patients and whether confounding factors were of influence. Methods: To this end, we measured the levels of endocannabinoids N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), and the endocannabinoid analogue docosahexaenoylethanolamine (DHEA) in the cerebrospinal fluid (CSF), obtained from 194 individuals with episodic migraine between attacks (97 migraine with aura and 97 migraine without aura individuals) and from 94 healthy volunteers, using micro-liquid chromatography – tandem mass spectrometry (micro-LC-MS/MS). Groups were age- and sex-matched. Timing and processing of sampling was protocolized. Multivariate linear regression analyses for log 10 -transformed endocannabinoid concentrations were performed to compare groups. Covariates that were included were sex, age, BMI, substance use and depressive symptoms. Results: No differences were detected between individuals with migraine with or without aura and healthy controls in the CSF for AEA ( p = 0.46, p = 0.08), 2-AG ( p = 0.46, p = 0.90) and DHEA ( p = 0.58, p = 0.79), respectively. For 2-AG, levels were, however, positively correlated with depressive symptoms (β = 0.053; 95% CI: 0.014 to 0.093, p = 0.008). Conclusion: CSF endocannabinoids (AEA, 2-AG, and DHEA) may not serve as effective biomarkers for distinguishing interictal episodic migraine patients from controls. Instead, CSF levels of 2-AG are linked to depressive symptoms, shedding further light on the relevance of endocannabinoids in patients with migraine and depression. This study highlights the intricate nature of the endocannabinoid system concerning episodic migraine and confounding factors.
- 10 July 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (7)
Open AccessEndocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression
Background: Disruption of the endocannabinoid system has been implicated in both migraine and depression, which are frequently comorbid in patients. Nevertheless, supporting evidence for this hypothesis is limited. Hence, we investigated whether the endocannabinoid system is disrupted in interictal migraine patients and whether confounding factors were of influence. Methods: To this end, we measured the levels of endocannabinoids N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), and the endocannabinoid analogue docosahexaenoylethanolamine (DHEA) in the cerebrospinal fluid (CSF), obtained from 194 individuals with episodic migraine between attacks (97 migraine with aura and 97 migraine without aura individuals) and from 94 healthy volunteers, using micro-liquid chromatography – tandem mass spectrometry (micro-LC-MS/MS). Groups were age- and sex-matched. Timing and processing of sampling was protocolized. Multivariate linear regression analyses for log 10 -transformed endocannabinoid concentrations were performed to compare groups. Covariates that were included were sex, age, BMI, substance use and depressive symptoms. Results: No differences were detected between individuals with migraine with or without aura and healthy controls in the CSF for AEA ( p = 0.46, p = 0.08), 2-AG ( p = 0.46, p = 0.90) and DHEA ( p = 0.58, p = 0.79), respectively. For 2-AG, levels were, however, positively correlated with depressive symptoms (β = 0.053; 95% CI: 0.014 to 0.093, p = 0.008). Conclusion: CSF endocannabinoids (AEA, 2-AG, and DHEA) may not serve as effective biomarkers for distinguishing interictal episodic migraine patients from controls. Instead, CSF levels of 2-AG are linked to depressive symptoms, shedding further light on the relevance of endocannabinoids in patients with migraine and depression. This study highlights the intricate nature of the endocannabinoid system concerning episodic migraine and confounding factors.
- Open Access
- 11 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9899
Correlation of Amine Concentrations in Blood and Cerebrospinal Fluid in Healthy Volunteers and Migraineurs
Many central nervous system disorders (CNS), including chronic pain and migraine, involve metabolic changes in the brain. These changes are best detected and monitored in cerebrospinal fluid (CSF), which requires lumbar puncture. Blood-based measurements may offer an alternative, if they reflect CSF changes. To assess this, we measured and correlated the concentrations of 39 amino acids, biogenic amines, and other amines in blood and CSF of 95 healthy volunteers and, in addition, correlated the ratios of 741 amines. Amines were measured using a validated UPLC-MS platform. In healthy volunteers, only 4/39 (10.3%) analyzed amine metabolite concentrations had a correlation coefficient ≥ 0.70. Correlations of metabolite ratios were significantly better for 308/741 (41.5%) combinations. Specifically, ratios of amino acids showed high correlations. In addition, amines were investigated in 197 participants with migraine. Six amine metabolite ratios were different in migraineurs versus healthy volunteers. Most blood amine concentrations do not reflect those in CSF, but many of the ratios did correlate between CSF and plasma, showing diagnostic potential. This study improves our understanding of blood-CSF relationships, and our data suggest that ratios of amines may be of relevance to CNS disorders, as we showed for migraine.
- 11 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9899
Open AccessCorrelation of Amine Concentrations in Blood and Cerebrospinal Fluid in Healthy Volunteers and Migraineurs
Many central nervous system disorders (CNS), including chronic pain and migraine, involve metabolic changes in the brain. These changes are best detected and monitored in cerebrospinal fluid (CSF), which requires lumbar puncture. Blood-based measurements may offer an alternative, if they reflect CSF changes. To assess this, we measured and correlated the concentrations of 39 amino acids, biogenic amines, and other amines in blood and CSF of 95 healthy volunteers and, in addition, correlated the ratios of 741 amines. Amines were measured using a validated UPLC-MS platform. In healthy volunteers, only 4/39 (10.3%) analyzed amine metabolite concentrations had a correlation coefficient ≥ 0.70. Correlations of metabolite ratios were significantly better for 308/741 (41.5%) combinations. Specifically, ratios of amino acids showed high correlations. In addition, amines were investigated in 197 participants with migraine. Six amine metabolite ratios were different in migraineurs versus healthy volunteers. Most blood amine concentrations do not reflect those in CSF, but many of the ratios did correlate between CSF and plasma, showing diagnostic potential. This study improves our understanding of blood-CSF relationships, and our data suggest that ratios of amines may be of relevance to CNS disorders, as we showed for migraine.
- Open Access
- 30 January 2023
- Published by Wiley in Annals of Neurology
- Vol. 93 (4) , 715-728
Cerebrospinal Fluid and Plasma Amine Profiles in Interictal Migraine
Objective: Impaired amine metabolism has been associated with the etiology of migraine, that is, why patients continue to get migraine attacks. However, evidence from cerebrospinal fluid (CSF) is lacking. Here, we evaluated individual amine levels, global amine profiles, and amine pathways in CSF and plasma of interictal migraine patients and healthy controls.Methods: CSF and plasma were sampled between 8:30 AM and 1:00 PM, randomly and interchangeably over the time span to avoid any diurnal and seasonal influences, from healthy volunteers and interictal migraine patients, matched for age, sex, and sampling time. The study was approved by the local medical ethics committee. Individual amines (n = 31), global amine profiles, and specific amine pathways were analyzed using a validated ultraperformance liquid chromatography mass spectrometry platform. Results: We analyzed n = 99 participants with migraine with aura, n = 98 with migraine without aura, and n = 96 healthy volunteers. Univariate analysis with Bonferroni correction indicated that CSF L-arginine was reduced in migraine with aura (10.4%, p < 0.001) and without aura (5.0%, p = 0.03). False discovery rate-corrected CSF L-phenylalanine was also lower in migraine with aura (6.9%, p = 0.011) and without aura (8.1%, p = 0.001), p = 0.088 after Bonferroni correction. Multivariate analysis revealed that CSF global amine profiles were similar for both types of migraine (p = 0.64), but distinct from controls (p = 0.009). Global profile analyses were similar in plasma. The strongest associated path-ways with migraine were related to L-arginine metabolism. Interpretation: L-Arginine was decreased in the CSF (but not in plasma) of interictal patients with migraine with or without aura, and associated pathways were altered. This suggests that dysfunction of nitric oxide signaling is involved in susceptibility to getting migraine attacks.
- 30 January 2023
- Published by Wiley in Annals of Neurology
- Vol. 93 (4) , 715-728
Open AccessCerebrospinal Fluid and Plasma Amine Profiles in Interictal Migraine
Objective: Impaired amine metabolism has been associated with the etiology of migraine, that is, why patients continue to get migraine attacks. However, evidence from cerebrospinal fluid (CSF) is lacking. Here, we evaluated individual amine levels, global amine profiles, and amine pathways in CSF and plasma of interictal migraine patients and healthy controls.Methods: CSF and plasma were sampled between 8:30 AM and 1:00 PM, randomly and interchangeably over the time span to avoid any diurnal and seasonal influences, from healthy volunteers and interictal migraine patients, matched for age, sex, and sampling time. The study was approved by the local medical ethics committee. Individual amines (n = 31), global amine profiles, and specific amine pathways were analyzed using a validated ultraperformance liquid chromatography mass spectrometry platform. Results: We analyzed n = 99 participants with migraine with aura, n = 98 with migraine without aura, and n = 96 healthy volunteers. Univariate analysis with Bonferroni correction indicated that CSF L-arginine was reduced in migraine with aura (10.4%, p < 0.001) and without aura (5.0%, p = 0.03). False discovery rate-corrected CSF L-phenylalanine was also lower in migraine with aura (6.9%, p = 0.011) and without aura (8.1%, p = 0.001), p = 0.088 after Bonferroni correction. Multivariate analysis revealed that CSF global amine profiles were similar for both types of migraine (p = 0.64), but distinct from controls (p = 0.009). Global profile analyses were similar in plasma. The strongest associated path-ways with migraine were related to L-arginine metabolism. Interpretation: L-Arginine was decreased in the CSF (but not in plasma) of interictal patients with migraine with or without aura, and associated pathways were altered. This suggests that dysfunction of nitric oxide signaling is involved in susceptibility to getting migraine attacks.
- Open Access
- 12 May 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (8) , 2631-2638
Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without
Background and purpose: This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception disorder (HPPD) presenting as visual snow syndrome (VSS).Methods: Persons with visual snow as a persisting symptom after illicit drug use (HPPD) were recruited via a Dutch consulting clinic for recreational drug use. A structured interview on (visual) perceptual symptomatology, details of drugs use, and medical and headache history was taken. As a control group, persons with visual snow who had never used illicit drugs prior to onset were included. The primary outcome was lifetime prevalence of migraine. Symptom severity was evaluated by the Visual Snow Handicap Inventory (VHI), a 25‐item questionnaire.Results: None of the 24 HPPD participants had migraine, whereas 20 of 37 (54.1%) controls had migraine (p < 0.001). VHI scores did not differ significantly between the two groups; in both groups, the median score was 38 of 100. In most HPPD cases (17/24, 70.9%), visual snow had started after intake of ecstasy; other psychedelic drugs reported included cannabis, psilocybin mushrooms, amphetamine, 4‐fluoroamphetamine, 3‐methylmethcathinone, 4‐Bromo‐2,5‐dimethoxypenethylamine, and nitrous oxide.Conclusions: Whereas none of the HPPD participants had migraine, more than half of the visual snow controls without prior use of illicit drugs had migraine. This suggests that at least partly different pathophysiological factors play a role in these disorders. Users of ecstasy and other hallucinogens should be warned of the risk of visual snow. Further studies are needed to enhance understanding of the underlying neurobiology of HPPD and VSS to enable better management of these conditions.
- 12 May 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (8) , 2631-2638
Open AccessMigraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without
Background and purpose: This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception disorder (HPPD) presenting as visual snow syndrome (VSS).Methods: Persons with visual snow as a persisting symptom after illicit drug use (HPPD) were recruited via a Dutch consulting clinic for recreational drug use. A structured interview on (visual) perceptual symptomatology, details of drugs use, and medical and headache history was taken. As a control group, persons with visual snow who had never used illicit drugs prior to onset were included. The primary outcome was lifetime prevalence of migraine. Symptom severity was evaluated by the Visual Snow Handicap Inventory (VHI), a 25‐item questionnaire.Results: None of the 24 HPPD participants had migraine, whereas 20 of 37 (54.1%) controls had migraine (p < 0.001). VHI scores did not differ significantly between the two groups; in both groups, the median score was 38 of 100. In most HPPD cases (17/24, 70.9%), visual snow had started after intake of ecstasy; other psychedelic drugs reported included cannabis, psilocybin mushrooms, amphetamine, 4‐fluoroamphetamine, 3‐methylmethcathinone, 4‐Bromo‐2,5‐dimethoxypenethylamine, and nitrous oxide.Conclusions: Whereas none of the HPPD participants had migraine, more than half of the visual snow controls without prior use of illicit drugs had migraine. This suggests that at least partly different pathophysiological factors play a role in these disorders. Users of ecstasy and other hallucinogens should be warned of the risk of visual snow. Further studies are needed to enhance understanding of the underlying neurobiology of HPPD and VSS to enable better management of these conditions.
- Open Access
- 30 July 2019
- Published by F1000 Research Ltd in F1000Research
- Vol. 8, 1219
Symptoms related to the visual system in migraine
Migraine is a common headache disorder characterized by often-severe headaches that may be preceded or accompanied by a variety of visual symptoms. Although a typical migraine aura is not difficult to diagnose, patients with migraine may report several other visual symptoms, such as prolonged or otherwise atypical auras, “visual blurring”, “retinal migraine”, “ophthalmoplegic migraine”, photophobia, palinopsia, and “visual snow”. Here, we provide a short overview of these symptoms and what is known about the relationship with migraine pathophysiology. For some symptoms, the association with migraine is still debated; for other symptoms, recent studies indicate that migraine mechanisms play a role.
- 30 July 2019
- Published by F1000 Research Ltd in F1000Research
- Vol. 8, 1219
Open AccessSymptoms related to the visual system in migraine
Migraine is a common headache disorder characterized by often-severe headaches that may be preceded or accompanied by a variety of visual symptoms. Although a typical migraine aura is not difficult to diagnose, patients with migraine may report several other visual symptoms, such as prolonged or otherwise atypical auras, “visual blurring”, “retinal migraine”, “ophthalmoplegic migraine”, photophobia, palinopsia, and “visual snow”. Here, we provide a short overview of these symptoms and what is known about the relationship with migraine pathophysiology. For some symptoms, the association with migraine is still debated; for other symptoms, recent studies indicate that migraine mechanisms play a role.
- Open Access
- 30 September 2016
- Published by SAGE Publications in Cephalalgia
- Vol. 37 (1) , 49-63
Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis
Objective: To perform a meta-analysis of migraine biomarkers in cerebrospinal fluid (CSF) and of corresponding blood concentrations. Methods: We conducted a systematic search for studies that measured biochemical compounds in CSF of chronic or episodic migraineurs and non-headache controls. Subsequent searches retrieved studies with blood measurements of selected CSF biomarkers. If a compound was assessed in three or more studies, results were pooled in a meta-analysis with standardised mean differences (SMD) as effect measures. Results: Sixty-two compounds were measured in 40 CSF studies. Most important results include: increased glutamate (five studies, SMD 2.22, 95% CI: 1.30, 3.13), calcitonin gene-related peptide (CGRP) (three studies, SMD: 3.80, 95% CI: 3.19, 4.41) and nerve growth factor (NGF) (three studies, SMD: 6.47, 95% CI: 5.55, 7.39) in chronic migraine patients and decreased β-endorphin (β-EP) in both chronic (four studies, SMD: –1.37, 95% CI: –1.80, –0.94) and interictal episodic migraine patients (three studies, SMD: –1.12, 95% CI: –1.65, –0.58). In blood, glutamate (interictal) and CGRP (chronic, interictal and ictal) were increased and β-EP (chronic, interictal and ictal) was decreased. Conclusions: Glutamate, β-EP, CGRP and NGF concentrations are altered in CSF and, except for NGF, also in blood of migraineurs. Future research should focus on the pathophysiological roles of these compounds in migraine.
- 30 September 2016
- Published by SAGE Publications in Cephalalgia
- Vol. 37 (1) , 49-63
Open AccessMigraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis
Objective: To perform a meta-analysis of migraine biomarkers in cerebrospinal fluid (CSF) and of corresponding blood concentrations. Methods: We conducted a systematic search for studies that measured biochemical compounds in CSF of chronic or episodic migraineurs and non-headache controls. Subsequent searches retrieved studies with blood measurements of selected CSF biomarkers. If a compound was assessed in three or more studies, results were pooled in a meta-analysis with standardised mean differences (SMD) as effect measures. Results: Sixty-two compounds were measured in 40 CSF studies. Most important results include: increased glutamate (five studies, SMD 2.22, 95% CI: 1.30, 3.13), calcitonin gene-related peptide (CGRP) (three studies, SMD: 3.80, 95% CI: 3.19, 4.41) and nerve growth factor (NGF) (three studies, SMD: 6.47, 95% CI: 5.55, 7.39) in chronic migraine patients and decreased β-endorphin (β-EP) in both chronic (four studies, SMD: –1.37, 95% CI: –1.80, –0.94) and interictal episodic migraine patients (three studies, SMD: –1.12, 95% CI: –1.65, –0.58). In blood, glutamate (interictal) and CGRP (chronic, interictal and ictal) were increased and β-EP (chronic, interictal and ictal) was decreased. Conclusions: Glutamate, β-EP, CGRP and NGF concentrations are altered in CSF and, except for NGF, also in blood of migraineurs. Future research should focus on the pathophysiological roles of these compounds in migraine.